From todays Practice Update here in full for those who are registered practiceupdate.com/journals...
or in brief:
Decline in Ovarian Cancer Incidence Associated With Decreased Use of Menopausal Hormone Therapy
An analysis of the North American Association of Central Cancer Registries database between 1995 and 2008 reported a decline in the age-standardized incidence rate of ovarian cancer from 38/100,000 in 1995 to 30/100,000 in 2008. A greater rate of decline was noted after 2002 when the use of hormone replacement therapy decreased.
Correlations between increased prevalence of hormone use and incidence of ovarian cancer provided evidence suggesting a causative relationship. Menopausal hormonal therapy (MHT) with estrogen only or combined estrogen plus progestin was associated with increased risk of ovarian cancer. A substantial decline in use of MHT with combined estrogen and progestin was associated with a decrease in breast cancer rates. This study evaluated trends in ovarian cancer incidence before and after results were reported from the Women's Health Initiative (WHI) that showed adverse health effects with combined estrogen plus progestin MHT.
Data for this analysis were obtained from the Cancer Incidence in North America (CINA) Analytic File for Expanded Races of the North American Association of Central Cancer Registries (NAACCR). Out of 240,912 ovarian tumors in the analytic file, 211,534 carcinomas were included in this analysis. Of the 192,075 ovarian cancers in women aged = 50 years, 171,142 were carcinomas. Population counts were based on the 2000 US census. Trends in incidence were evaluated using joinpoint regression analysis and age-period-cohort models that adjusted for age and birth cohort.